Gut bacteria tied to MS inflammation — a new clue

Credibility

Interest

Share:2 min read

Key Takeaway

A common gut microbe, Akkermansia muciniphila, can help other gut bacteria change tryptophan into molecules that boost a type of immune response linked to worse MS-like inflammation.

What They Found

People with relapsing-remitting MS had signs their gut barrier was weaker, shown by higher blood levels of LPS (a bacterial component) and antibodies against it; think of LPS like crumbs leaking from a broken gut wall. These MS patients also had more immune reactions to Akkermansia muciniphila, a mucin-eating gut microbe, meaning their immune cells made more Th17-type responses (Th17 are immune cells that can cause inflammation). In a mouse model of MS, adding A. muciniphila made disease worse and increased Th17 and related inflammatory immune cells in the spinal cord. A. muciniphila did not eat tryptophan itself, but by breaking down mucin (the mucus layer that lines the gut) it helped another bacterium, Alistipes onderdonkii, grow and use tryptophan. That partnership raised levels of small tryptophan breakdown products (called indole derivatives) that activate the AhR receptor and promote the Th17 inflammation linked to nerve damage; cutting dietary tryptophan reduced disease in the mice.

Who Should Care and Why

MS patients and caregivers should care because the study links gut microbes and what they eat to immune changes that can make MS-like inflammation worse; this suggests the gut environment can affect brain and spinal cord health. Doctors and dietitians might use this idea to explore whether changing diet or gut bacteria could help manage symptoms, similar to how changing soil can help a garden grow healthier plants. Caregivers could consider discussing gut-focused strategies with healthcare teams, since small diet changes or probiotics might eventually become part of care. People with weakened gut barriers (signs like food sensitivity or gut symptoms) might be more affected, because a leaky gut lets bacterial pieces and signals reach the immune system. The findings matter for daily life because they point to actions — like consulting clinicians about diet, gut health, or testing — that could one day reduce harmful immune reactions.

Important Considerations

This study used a mouse model that mimics some but not all features of human MS, so results may not work exactly the same in people. The findings show a link between certain gut bacteria and immune changes, but they do not prove that changing bacteria or diet will definitely help MS patients yet. More human studies are needed before making treatment changes based on these results.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Genetics MS Progression

Article Topics:

Akkermansia muciniphilaEAETh17 cells

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Mucosal immunology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News